Image Box LS PR

@ImageBoxLSPR

Image Box LS PR - the arm of Image Box PR, the and and agency with a full service product portfolio and client base.

Kingston, London, UK
Vrijeme pridruživanja: lipanj 2014.

Tweetovi

Blokirali ste korisnika/cu @ImageBoxLSPR

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ImageBoxLSPR

  1. 3. velj

    Orgenesis sells Masthercell Global, its contract development and manufacturing organisation subsidiary. Will use $127 million to continue to grow its point-of-care business and to further the development of its .

    Poništi
  2. proslijedio/la je Tweet
    29. sij

    Akron's Ezequiel Zylberberg, along w/ co-authors Richard Harrison, & , examines cost of goods associated w/ allogeneic CAR-T cell therapy manufacturing & delivery, modeling differentials across regions. A look at their findings:

    Poništi
  3. 13. sij

    Orgenesis appoints industry veteran Mario Philips, PolyNeuroS CEO, Archimed strategic partner and chair of board for Clean Biologics, to its board of directors

    Poništi
  4. 13. sij

    Orgenesis announces addition of University of California, Davis, to its Point of Care network; UC Davis Health to utilize Orgenesis’ Point of Care platform for the development, commercialization and supply of cell and gene therapy products

    Poništi
  5. 19. pro 2019.

    Zelluna Immunotherapy, the biopharma company developing receptor guided adoptive products for treatment of multiple solid , today appoints Namir Hassan as chief executive officer ().

    Poništi
  6. 16. pro 2019.

    Major cell and gene therapy supplement - Miguel Forte, Zelluna & on why TCRs have potential to expand on CAR-Ts & treat solid tumours

    Poništi
  7. 16. pro 2019.

    Major cell and gene therapy supplement - Vered Caplan, Orgenesis outlines cost reduction to if & healthcare providers engaged in own process and development to treat their own

    Poništi
  8. 16. pro 2019.

    Major cell and gene therapy supplement - Gabriel Festoc, outlines importance of GMP-grade reagents to the entire and therapy sector.

    Poništi
  9. 16. pro 2019.

    Major cell and gene therapy supplement - 4-way interview including on key considerations for the sector, including the talent gap and how it affects every element of the sector.

    Poništi
  10. 16. pro 2019.

    Major cell and gene therapy supplement - in-depth article on Ravi Nalliah, CEO, covering the past, present and future of TrakCel and the and sector.

    Poništi
  11. 16. pro 2019.

    Major highlight of the year: supplement is published, & has secured key articles for & 3 leaders, Ravi Nalliah, , Orgenesis, Zelluna &

    Poništi
  12. 29. stu 2019.

    Orgenesis Ranked 5th Fastest Growing Technology Company in Maryland and 208th in North America on 'Deloitte's 2019 Technology Fast 500'

    Poništi
  13. 19. stu 2019.

    Zelluna Immunotherapy and Glycostem Therapeutics partner to develop allogeneic TCR-NK therapies

    Poništi
  14. 13. stu 2019.

    Orgenesis CEO Vered Caplan appears as a guest on “Israel Business Weekly” segment of Isreali i24 news network discussing how to transform the & market & lower costs to deliver potentially life-saving to

    Poništi
  15. 8. stu 2019.

    Orgenesis Q3 2019 revenue increases 46% to record $9.1 million - strong year-over-year growth result of traction gaining from CDMO business & evolving POCare platform

    Poništi
  16. 8. stu 2019.

    Immutep presents +ve interim PhII TACTI-002 trial data with Merck & Co (MSD), combining LAG-3 immunotherapy and Keytruda targeting lung cancer, running concurrently to other trials including with Pfizer, Merck & EOC & outlicenced trials with Novartis & GSK

    Poništi
  17. proslijedio/la je Tweet
    21. lis 2019.

    ISCT forms cell and gene therapy sector-wide coalition to combat the rise of unproven commercial cell banking services

    Poništi
  18. 16. lis 2019.

    Orgenesis agrees co-development deal with Accellix to integrate proprietary optic system into Orgenesis’ Point of Care (“POCare”) processing services and platform

    Poništi
  19. 2. lis 2019.

    Excellent to arrange interviews for major report from on the advanced capabilities needed to succeed after approval, for Bruce Levine, , , and Vered Caplan, Orgenesis.

    Poništi
  20. 30. ruj 2019.

    Great to get Miguel Forte, Zelluna Immunotherapy, and Marc Voigt, , covered in brilliant article reacting to UK Labour leader unveiling policy for the pharma sector by Madeleine Armstrong, for Vantage, .

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·